Traders should await the earnings call for actual financial results and clinical development updates. Until then, no actionable data is available.
Price Chart
Executive Summary
NRx Pharmaceuticals announced it will host a conference call to discuss its fiscal year 2025 financial results and provide updates on its drug development programs, including NRX-100 and NRX-101. The press release contains no actual financial data, only forward-looking statements and procedural details about the earnings call.
Key Facts
- NRx Pharmaceuticals will host an earnings call on March 24, 2026, to discuss FY2025 results.
- No financial figures (revenue, EPS, etc.) were disclosed in the press release.
- Company highlighted progress in drug development programs and regulatory designations for NRX-100 and NRX-101.
- Forward-looking statements dominate the release; no material financial or operational data provided.
Financial Impact
No financial impact can be assessed — no quantitative results disclosed.
Risk Factors
- Lack of disclosed financials increases uncertainty ahead of the call.
- Forward-looking statements may create expectations that are not met during the actual call.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258835 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access